C4 Therapeutics (CCCC) Accounts Payables (2019 - 2026)

C4 Therapeutics' Accounts Payables history runs 8 years deep, the most recent figure standing at $773000.0 for Q1 2026.

• On a quarterly basis, Accounts Payables rose 13.18% year-over-year to $773000.0 in Q1 2026; TTM through Mar 2026 was $773000.0, a 13.18% increase from a year earlier, with the FY2025 full-year figure at $858000.0, down 35.39% from the prior year.
• Accounts Payables declined to $773000.0 in Q1 2026 per CCCC's latest filing, from $858000.0 in the prior quarter.
• Across five years, Accounts Payables topped out at $4.4 million in Q2 2022 and bottomed at $683000.0 in Q1 2025.
• The 5-year median for Accounts Payables is $1.3 million (2025), against an average of $1.7 million.
• Across the five-year window, Accounts Payables sank 73.99% in 2022 and surged 142.72% in 2025, its largest moves.
• Year by year, Accounts Payables stood at $1.2 million in 2022, then increased by 23.38% to $1.4 million in 2023, then retreated by 8.16% to $1.3 million in 2024, then plunged by 35.39% to $858000.0 in 2025, then slipped by 9.91% to $773000.0 in 2026.
• Per Business Quant, the three latest CCCC Accounts Payables figures stand at $773000.0 (Q1 2026), $858000.0 (Q4 2025), and $1.3 million (Q3 2025).